NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.21 -0.17 (-3.88 %) (As of 10/16/2018 06:56 AM ET)Previous Close$4.38Today's Range$4.16 - $4.4252-Week Range$3.98 - $11.93Volume97,200 shsAverage Volume363,727 shsMarket Capitalization$161.39 millionP/E Ratio13.65Dividend YieldN/ABeta1.75 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland. Receive AVDL News and Ratings via Email Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:AVDL CUSIPN/A Webwww.avadel.com Phone636-449-1830 Debt Debt-to-Equity Ratio1.44 Current Ratio3.39 Quick Ratio3.28 Price-To-Earnings Trailing P/E Ratio13.65 Forward P/E Ratio-2.20 P/E GrowthN/A Sales & Book Value Annual Sales$172.74 million Price / Sales0.90 Cash Flow$0.4296 per share Price / Cash9.80 Book Value$2.18 per share Price / Book1.93 Profitability EPS (Most Recent Fiscal Year)$0.31 Net Income$68.27 million Net Margins-2.39% Return on Equity-46.58% Return on Assets-13.75% Miscellaneous Employees169 Outstanding Shares36,760,000Market Cap$161.39 million Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions What is Avadel Pharmaceuticals' stock symbol? Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL." How will Avadel Pharmaceuticals' stock buyback program work? Avadel Pharmaceuticals announced that its board has approved a stock repurchase program on Wednesday, March 28th 2018, which allows the company to buyback $7,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.7% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's board of directors believes its stock is undervalued. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals PLC (NASDAQ:AVDL) announced its quarterly earnings data on Tuesday, August, 7th. The company reported ($0.09) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.37) by $0.28. The company had revenue of $29.23 million for the quarter, compared to analyst estimates of $25.02 million. Avadel Pharmaceuticals had a negative net margin of 2.39% and a negative return on equity of 46.58%. View Avadel Pharmaceuticals' Earnings History. When is Avadel Pharmaceuticals' next earnings date? Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for Avadel Pharmaceuticals. What price target have analysts set for AVDL? 4 brokerages have issued 12-month price objectives for Avadel Pharmaceuticals' shares. Their forecasts range from $14.00 to $24.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 351.3% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals. What is the consensus analysts' recommendation for Avadel Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals. Who are some of Avadel Pharmaceuticals' key competitors? Some companies that are related to Avadel Pharmaceuticals include Basilea Pharmaceutica (BPMUF), Vectura Group (VEGPF), ChemoCentryx (CCXI), GlycoMimetics (GLYC), Arcus Biosciences (RCUS), ArQule (ARQL), Abeona Therapeutics (ABEO), Dova Pharmaceuticals (DOVA), Ra Pharmaceuticals (RARX), Aduro BioTech (ADRO), Aurinia Pharmaceuticals (AUPH), Beyondspring (BYSI), TIGENIX/S (TIG), Adamas Pharmaceuticals (ADMS) and Cytokinetics (CYTK). Who are Avadel Pharmaceuticals' key executives? Avadel Pharmaceuticals' management team includes the folowing people: Mr. Michael S. Anderson, CEO & Director (Age 69)Mr. Michael F. Kanan, Sr. VP & CFO (Age 55)Mr. Gregory J. Divis, Exec. VP & COO (Age 53)Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)Dr. David Monteith, VP of R&D (Age 54) How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Avadel Pharmaceuticals' stock price today? One share of AVDL stock can currently be purchased for approximately $4.21. How big of a company is Avadel Pharmaceuticals? Avadel Pharmaceuticals has a market capitalization of $161.39 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 169 workers across the globe. What is Avadel Pharmaceuticals' official website? The official website for Avadel Pharmaceuticals is http://www.avadel.com. How can I contact Avadel Pharmaceuticals? Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected] MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 204 (Vote Outperform)Underperform Votes: 181 (Vote Underperform)Total Votes: 385MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/16/2018 by MarketBeat.com StaffFeatured Article: What is intrinsic value?